Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

DORADO-EX - A Dose-Blinded, Long-Term Safety Extension Study of Fixed Doses of Darusentan in Subjects With Resistant Systolic Hypertension Receiving Combination Therapy With Three or More Antihypertensive Drugs, Including a Diuretic (Protocol DAR-311-E)

NCT00353574 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT00353574
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00353574 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
DORADO-EX - A Dose-Blinded, Long-Term Safety Extension Study of Fixed Doses of Darusentan in Subjects With Resistant Systolic Hypertension Receiving Combination Therapy With Three or More Antihypertensive Drugs, Including a Diuretic (Protocol DAR-311-E)
Lead sponsor
Gilead Sciences
Phase
Phase 3
Overall status
Terminated
Start date
September 30, 2006
Completion date
April 30, 2010
Enrollment
282 (actual)
Sites
75

Conditions

As the registry lists them; a condition with its own page is linked.

hypertension